Jean-Louis Beaudeux1, Valérie Nivet-Antoine, Philippe Giral. 1. EA 4466 Stress cellulaire: physiopathologie, stratégies nutritionnelles et innovations thérapeutiques, Faculté de Pharmacie Paris Descartes, hôpital Charles Foix, APHP, Paris, France.
Abstract
PURPOSE OF REVIEW: The metabolic syndrome is associated with increased risk for development of both cardiovascular disease and type 2 diabetes in humans. Because experimental data and clinical experience have shown that metabolic syndrome and caloric restriction have, at least partly, opposite pathophysiological pathways, the activation of sirtuins may constitute a pharmacological approach to treat metabolic syndrome. Resveratrol is a polyphenol produced by plants that has multiple beneficial activities similar to those associated with caloric restriction. RECENT FINDINGS: Through its regulatory action of both AMP kinase and the sirtuin sirtuin-1, resveratrol is a natural sirtuin activator that certainly will be the head of a new pharmacological family of drugs targeted on sirtuin-1 activity exacerbation in order to treat/protect from obesity and diabetes, and thus metabolic syndrome. SUMMARY: This review discusses the therapeutic use of resveratrol and sirtuin activators in the context of insulin resistance and obesity, the two main features of metabolic syndrome.
PURPOSE OF REVIEW: The metabolic syndrome is associated with increased risk for development of both cardiovascular disease and type 2 diabetes in humans. Because experimental data and clinical experience have shown that metabolic syndrome and caloric restriction have, at least partly, opposite pathophysiological pathways, the activation of sirtuins may constitute a pharmacological approach to treat metabolic syndrome. Resveratrol is a polyphenol produced by plants that has multiple beneficial activities similar to those associated with caloric restriction. RECENT FINDINGS: Through its regulatory action of both AMP kinase and the sirtuin sirtuin-1, resveratrol is a natural sirtuin activator that certainly will be the head of a new pharmacological family of drugs targeted on sirtuin-1 activity exacerbation in order to treat/protect from obesity and diabetes, and thus metabolic syndrome. SUMMARY: This review discusses the therapeutic use of resveratrol and sirtuin activators in the context of insulin resistance and obesity, the two main features of metabolic syndrome.
Authors: Sakhila K Banu; Jone A Stanley; Kirthiram K Sivakumar; Joe A Arosh; Robert C Burghardt Journal: Toxicol Appl Pharmacol Date: 2016-04-27 Impact factor: 4.219
Authors: Esperanza Martínez-Abundis; Miriam Méndez-Del Villar; Karina G Pérez-Rubio; Laura Y Zuñiga; Marisol Cortez-Navarrete; Alejandra Ramírez-Rodriguez; Manuel González-Ortiz Journal: World J Diabetes Date: 2016-04-10